Subscribe To
89bio's low price presents an opportunity
89bio, Inc. stock dropped along with other NASH players after Akero's efruxifermin failed a phase 2 tri...
October 26, 2023, 2:15 pm
89bio to participate in the h.c. wainwright 7ᵗʰ annual nash investor conference
SAN FRANCISCO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharma...
October 17, 2023, 8:00 am
Why shares of 89bio plummeted on tuesday
89bio is a clinical-stage biotech company. It focuses on treatments for liver and cardiometabolic disea...
October 10, 2023, 4:13 pm
89bio earns ‘buy' rating in initial coverage on positive prospects for nash therapeutic
Analysts at UBS have initiated coverage on 89bio (ETNB) with a ‘Buy' rating and a US$36 price target,...
August 28, 2023, 3:01 pm
89bio, inc.: a big bet on nash
89bio, Inc. is a clinical-stage biotech company focused on developing therapies for liver and cardio-me...
August 10, 2023, 1:48 pm
89bio publishes positive results from phase 2 entrigue trial of pegozafermin in patients with severe hypertriglyceridemia (shtg) in nature medicine
– Published data showed consistent and significant reductions in triglycerides, atherogenic lipoproteins and liver fat, and pegozafermin’s favorab...
June 24, 2023, 9:05 am
Data from 89bio’s enliven phase 2b trial of pegozafermin in patients with nonalcoholic steatohepatitis (nash) published in the new england journal of medicine and simultaneously presented in a late-br
– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in statistically significant chan...
June 24, 2023, 9:01 am
Data from 89bio’s enliven phase 2b trial of pegozafermin in patients with nonalcoholic steatohepatitis (nash) published in the new england journal of medicine and simultaneously presented in a late-br
– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in statistically significant chan...
June 24, 2023, 9:01 am
Data from 89bio’s enliven phase 2b trial of pegozafermin in patients with nonalcoholic steatohepatitis (nash) published in the new england journal of medicine and simultaneously presented in a late-br
– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in statistically significant chan...
June 24, 2023, 9:01 am
Data from 89bio’s enliven phase 2b trial of pegozafermin in patients with nonalcoholic steatohepatitis (nash) published in the new england journal of medicine and simultaneously presented in a late-br
– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in statistically significant chan...
June 24, 2023, 9:01 am
Data from 89bio’s enliven phase 2b trial of pegozafermin in patients with nonalcoholic steatohepatitis (nash) published in the new england journal of medicine and simultaneously presented in a late-br
– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in statistically significant chan...
June 24, 2023, 9:01 am
Data from 89bio’s enliven phase 2b trial of pegozafermin in patients with nonalcoholic steatohepatitis (nash) published in the new england journal of medicine and simultaneously presented in a late-br
– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in statistically significant chan...
June 24, 2023, 9:01 am
89bio shares rise as analysts see improved outlook for nash treatments
Shares of clinical-stage biopharma company 89bio Inc. ETNB, +4.38% gained 4.8% premarket on Tuesday as ...
June 13, 2023, 8:29 am
89bio (etnb) just overtook the 20-day moving average
89bio (ETNB) is looking like an interesting pick from a technical perspective, as the company reached a...
May 29, 2023, 10:50 am
89bio: great prospects after excellent phase 2 data
ETNB posted excellent phase 2 data in March. They plan to start a phase 3 trial now....
May 28, 2023, 4:18 am
Is allogene therapeutics (allo) stock outpacing its medical peers this year?
Here is how Allogene Therapeutics (ALLO) and 89bio (ETNB) have performed compared to their sector so fa...
May 5, 2023, 11:23 am
Wall street analysts predict a 57.05% upside in 89bio (etnb): here's what you should know
The mean of analysts' price targets for 89bio (ETNB) points to a 57.1% upside in the stock. While this ...
May 5, 2023, 11:23 am
3 biotech buyout targets to watch
89bio's stock is up more than 21% this year. Karuna Therapeutics says it plans to file an NDA for its l...
April 29, 2023, 8:25 am
Is 89bio (etnb) outperforming other medical stocks this year?
Here is how 89bio (ETNB) and Henry Schein (HSIC) have performed compared to their sector so far this ye...
April 13, 2023, 11:25 am
Ra capital management now owns 18% of 89bio
Fintel reports that Ra Capital Management has filed a 13D/A form with the SEC disclosing ownership of 12.88MM shares of ...
March 31, 2023, 10:31 pm